Literature DB >> 31613369

Follow-up Care for Breast Cancer Survivors.

Kathryn J Ruddy1, Jeph Herrin2, Lindsey Sangaralingham3,4, Rachel A Freedman5,6, Ahmedin Jemal7,8, Tufia C Haddad1, Summer V Allen9, Tina Hieken10, Judy C Boughey10, Patricia A Ganz6,11, Rachel D Havyer5, Nilay D Shah7,4.   

Abstract

Breast cancer survivorship guidelines recommend at least annual follow-up visits, yet the degree to which this occurs in clinical practice is uncertain. Claims data from a US commercial insurance database (OptumLabs) were used to identify women treated with curative intent surgery for newly diagnosed breast cancer between 2006 and 2014. In 25 035 women, median follow-up was 3 years. In the second year after surgery, 9.6% of the patients did not visit a primary care provider, an oncologist, or a surgeon (guideline-nonadherent). The guideline-nonadherent proportion increased from 7.8% in women diagnosed in 2006 to 12.2% in those diagnosed in 2014 (two-sided Wald P < .001). During years 2-6, guideline-nonadherence was also associated with older age, nonwhite race, no radiation, no chemotherapy, no endocrine therapy, and increasing time after surgery. There is a substantial and increasing rate of inadequate follow-up among breast cancer survivors. This has the potential to impair outcomes.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 31613369      PMCID: PMC7849972          DOI: 10.1093/jnci/djz203

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  8 in total

1.  NCCN Guidelines Updates: Breast Cancer.

Authors:  Sharon H Giordano; Anthony D Elias; William J Gradishar
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

2.  An algorithm for the use of Medicare claims data to identify women with incident breast cancer.

Authors:  Ann B Nattinger; Purushottam W Laud; Ruta Bajorunaite; Rodney A Sparapani; Jean L Freeman
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

4.  Randomized phase 2 trial of a coordinated breast cancer follow-up care program.

Authors:  Kathryn J Ruddy; Hao Guo; Emily L Baker; Matthew J Goldstein; Erin E Mullaney; Lawrence N Shulman; Ann H Partridge
Journal:  Cancer       Date:  2016-07-26       Impact factor: 6.860

5.  Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.

Authors:  Heather T Gold; Huong T Do
Journal:  Health Serv Res       Date:  2007-10       Impact factor: 3.402

6.  Optum Labs: building a novel node in the learning health care system.

Authors:  Paul J Wallace; Nilay D Shah; Taylor Dennen; Paul A Bleicher; Paul D Bleicher; William H Crown
Journal:  Health Aff (Millwood)       Date:  2014-07       Impact factor: 6.301

Review 7.  American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Authors:  Carolyn D Runowicz; Corinne R Leach; N Lynn Henry; Karen S Henry; Heather T Mackey; Rebecca L Cowens-Alvarado; Rachel S Cannady; Mandi L Pratt-Chapman; Stephen B Edge; Linda A Jacobs; Arti Hurria; Lawrence B Marks; Samuel J LaMonte; Ellen Warner; Gary H Lyman; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

8.  Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.

Authors:  Alexis D Leal; Holly Van Houten; Lindsey Sangaralingham; Rachel A Freedman; Ahmedin Jemal; Heather B Neuman; Tufia C Haddad; Robert W Mutter; Theresa H M Keegan; Sarah S Mougalian; Charles L Loprinzi; Cary P Gross; Nilay Shah; Kathryn J Ruddy
Journal:  Clin Breast Cancer       Date:  2017-09-22       Impact factor: 3.225

  8 in total
  2 in total

1.  Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort.

Authors:  Paula Santiá; Anna Jansana; Isabel Del Cura; Maria Padilla-Ruiz; Laia Domingo; Javier Louro; Mercè Comas; Teresa Sanz; Talita Duarte-Salles; Maximino Redondo; Berta Ibañez; Alexandra Prados-Torres; Xavier Castells; Maria Sala
Journal:  Breast Cancer Res Treat       Date:  2022-03-15       Impact factor: 4.624

2.  Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.

Authors:  Ke-Da Yu; Jing-Yu Ge; Xi-Yu Liu; Miao Mo; Min He; Zhi-Ming Shao
Journal:  J Natl Cancer Inst       Date:  2021-10-01       Impact factor: 13.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.